brain_imagination-2560x1440
NASH
August 27, 2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

(Oral presentation, EASL International Liver Congress, 27-29 August 2020, Abstract #AS074)
Read More
NASH
August 27, 2020

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

(Poster, EASL International Liver Congress, 27-29 August 2020, Abstract #SAT038)
Read More
NASH
December 18, 2019

First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities

(Paper, Hepatology 2020)
Read More
NASH
September 6, 2019

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

(Poster, Obesity Week, 11-15 November 2018, Abstract # T-P-3383)
Read More
NASH
September 5, 2019

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

(Poster, AASLD The Liver Meeting, 9-13 November 2018, Abstract #734)
Read More
NASH
September 3, 2019

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

(Poster, ASCO Annual Meeting, 31 May – 4 June 2019, Abstract #2064)
Read More
NASH
February 13, 2018

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

(Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)
Read More
NASH
May 2, 2017

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment

(Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)
Read More